Marker Therapeutics, Inc.

Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.

MRKR | US

Overview

Corporate Details

ISIN(s):: US57055L1070 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://markertherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, non-genetically modified T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology, Multi-Antigen Recognizing (MAR) T cells, expands a patient's natural T cells to recognize and eliminate tumors expressing multiple antigens. This approach aims to provide durable anti-tumor responses with a favorable safety profile compared to genetically engineered cell therapies. The technology was developed at Baylor College of Medicine. Its lead product candidate, MT-601, is being evaluated in a Phase 1 study for lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Marker Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marker Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Marker Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Nanexa AB Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.	Sweden	NANEXA
Nanobiotix Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.	France	NANO
Nanobiotix S.A. Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.	United States of America	NBTX
Nanoform Finland OYJ Pharma tech firm engineering nanoparticles to enhance drug performance and development.	Finland	NANOFH
NanoGroup S.A. Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.	Poland	NNG
NanoRepro AG Develops and distributes rapid diagnostic self-tests for early disease detection.	Germany	NN6
NANOVIRICIDES, INC. Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.	United States of America	NNVC
Nasus Pharma Ltd Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.	United States of America	NSRX
NATAC Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.	Spain	NAT
Natera, Inc. Provides non-invasive cfDNA tests for oncology, women's health, and organ health.	United States of America	NTRA